KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Long-Term Investments (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Long-Term Investments for 5 consecutive years, with $28.4 million as the latest value for Q3 2025.

  • Quarterly Long-Term Investments changed N/A to $28.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $28.4 million through Sep 2025, changed N/A year-over-year, with the annual reading at $2.0 million for FY2023, 96.28% down from the prior year.
  • Long-Term Investments hit $28.4 million in Q3 2025 for CRISPR Therapeutics AG, up from $11.2 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $77.1 million in Q3 2022 to a low of $2.0 million in Q4 2023.
  • Historically, Long-Term Investments has averaged $23.9 million across 4 years, with a median of $9.8 million in 2022.
  • Biggest five-year swings in Long-Term Investments: plummeted 96.28% in 2023 and later skyrocketed 128.52% in 2024.
  • Year by year, Long-Term Investments stood at $53.1 million in 2022, then crashed by 96.28% to $2.0 million in 2023, then skyrocketed by 467.66% to $11.2 million in 2024, then skyrocketed by 153.57% to $28.4 million in 2025.
  • Business Quant data shows Long-Term Investments for CRSP at $28.4 million in Q3 2025, $11.2 million in Q2 2024, and $2.0 million in Q4 2023.